The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Switching chemotherapy in adult osteosarcoma patients with poor necrosis rates post neoadjuvant methotrexate, cisplatin, and doxorubicin (MAP).
Grainne O'Kane
No relevant relationships to disclose
Karen Anne Cadoo
No relevant relationships to disclose
Elaine Walsh
No relevant relationships to disclose
Conor O'Keane
No relevant relationships to disclose
Gary O'Toole
No relevant relationships to disclose
Sean Dudney
No relevant relationships to disclose
Desmond Carney
No relevant relationships to disclose